Interventional cardiology

Argon Strengthens Biopsy Portfolio with SuperCore Advantage™ Instrument

Retrieved on: 
Wednesday, May 31, 2023

PLANO, Texas, May 31, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, announced the launch of the SuperCore Advantage™ Semi-Automatic Biopsy Instrument as the newest addition to its soft tissue biopsy product portfolio in the United States.

Key Points: 
  • PLANO, Texas, May 31, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, announced the launch of the SuperCore Advantage™ Semi-Automatic Biopsy Instrument as the newest addition to its soft tissue biopsy product portfolio in the United States.
  • The SuperCore Advantage is a disposable, next generation soft tissue biopsy instrument that provides a superior volume of tissue samples*.
  • Adding the SuperCore Advantage to this portfolio among other segment leaders like the BioPince Ultra® Full Core Biopsy Instrument, will fortify our reputation as a leading provider of soft tissue biopsy devices," said Tom Younker, Senior Vice President of Global Marketing, Argon Medical.
  • Argon also offers the SuperCore™ Semi-Automatic, Tru-Core™ Automatic and Pro-Mag™ Ultra Biopsy Instruments.

Fortis Healthcare recognized for its contribution in positioning India as the Medical Tourism Hub; Conferred with 7 Awards

Retrieved on: 
Tuesday, May 23, 2023

NEW DELHI, May 23, 2023 /PRNewswire/ -- India's leading hospital chain, Fortis Healthcare has been recognized for its contribution in positioning India as the preferred medical tourism destination by Advantage Health Care India. Fortis bagged awards in 7 out of 12 categories - out of which Fortis Memorial Research Institute, Gurugram bagged 4 awards in Bone Marrow Transplant, Medical Oncology, Surgical Oncology and Neurosciences; Fortis Escorts Heart Institute, Okhla bagged 2 awards in Paediatric Cardiac Sciences (Cardiology and Cardiac Surgery) and Interventional Cardiology and Fortis Hospital, Noida bagged 1 award in liver transplant.

Key Points: 
  • Fortis was awarded by Advantage Health Care India - an International Summit, which was organized from 26th - 28thApril 2023
    NEW DELHI, May 23, 2023 /PRNewswire/ -- India's leading hospital chain, Fortis Healthcare has been recognized for its contribution in positioning India as the preferred medical tourism destination by Advantage Health Care India.
  • Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said "This is a proud moment for the Fortis group.
  • We have always been at the forefront to provide the best of medical services to foreign patients who avail our medical services.
  • The cost-effective treatment, highly skilled healthcare professionals, world-class infrastructure, easy travel accessibility along with language proficiency makes Fortis the most preferred destination for medical tourism."

Fortis Healthcare recognized for its contribution in positioning India as the Medical Tourism Hub; Conferred with 7 Awards

Retrieved on: 
Tuesday, May 23, 2023

NEW DELHI, May 23, 2023 /PRNewswire/ -- India's leading hospital chain, Fortis Healthcare has been recognized for its contribution in positioning India as the preferred medical tourism destination by Advantage Health Care India. Fortis bagged awards in 7 out of 12 categories - out of which Fortis Memorial Research Institute, Gurugram bagged 4 awards in Bone Marrow Transplant, Medical Oncology, Surgical Oncology and Neurosciences; Fortis Escorts Heart Institute, Okhla bagged 2 awards in Paediatric Cardiac Sciences (Cardiology and Cardiac Surgery) and Interventional Cardiology and Fortis Hospital, Noida bagged 1 award in liver transplant.

Key Points: 
  • Fortis was awarded by Advantage Health Care India - an International Summit, which was organized from 26th - 28thApril 2023
    NEW DELHI, May 23, 2023 /PRNewswire/ -- India's leading hospital chain, Fortis Healthcare has been recognized for its contribution in positioning India as the preferred medical tourism destination by Advantage Health Care India.
  • Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said "This is a proud moment for the Fortis group.
  • We have always been at the forefront to provide the best of medical services to foreign patients who avail our medical services.
  • The cost-effective treatment, highly skilled healthcare professionals, world-class infrastructure, easy travel accessibility along with language proficiency makes Fortis the most preferred destination for medical tourism."

Shockwave Appoints Kevin Ballinger to Board of Directors

Retrieved on: 
Wednesday, May 17, 2023

“I am excited to welcome Kevin to our Board of Directors,” said Ray Larkin, Chairman of Shockwave Board of Directors.

Key Points: 
  • “I am excited to welcome Kevin to our Board of Directors,” said Ray Larkin, Chairman of Shockwave Board of Directors.
  • He also served as a member of Aldevron’s board of directors from July 2020 until the acquisition by Danaher.
  • Mr. Ballinger has served on the board of directors of Silk Road Medical, Inc., a medical device company, since December 2020.
  • “Shockwave Medical is a true leader in the medical device industry, and I am honored to join this incredible team as a member of the Board of Directors,” said Mr. Ballinger.

Philips’ image-guided navigation increases safety during coronary interventions and reduces the use of contrast media by an average of 28.8%

Retrieved on: 
Tuesday, May 16, 2023

Iodine contrast media is used to visualize the coronary arteries during PCI procedures, but it can potentially harm the kidneys, risking the development of contrast-induced acute kidney injury (CI-AKI) after the procedure.

Key Points: 
  • Iodine contrast media is used to visualize the coronary arteries during PCI procedures, but it can potentially harm the kidneys, risking the development of contrast-induced acute kidney injury (CI-AKI) after the procedure.
  • “Enabling physicians to decrease contrast administration during procedures with tools like DCR could make a significant contribution to both the safety and quality of PCI.
  • “At Philips, we are committed to championing technologies that improve the patient’s experience, improve their safety and expand access to procedures to new patient groups.
  • Temporal Trends in Coronary Angiography and Percutaneous Coronary Intervention: Insights From the VA Clinical Assessment, Reporting, and Tracking Program.

GENESIS MEDTECH NAMES INAUGURAL PRESIDENT TO DRIVE COMMERCIAL STRATEGY FOR NORTH AMERICA

Retrieved on: 
Monday, May 15, 2023

SINGAPORE, MAY 15, 2023 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) is pleased to announce its appointment of Dr. Mark A. Turco (Dr. Turco), M.D., F.A.C.C., as President of Genesis MedTech Intervention, North America and CEO of JC Medical, Inc. Dr. Turco will lead the commercial strategy for the Vascular Interventions and Structural Heart Franchises in North America, catalysing Genesis' mission to bring innovative medical technologies to healthcare practitioners and patients.

Key Points: 
  • SINGAPORE, MAY 15, 2023 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) is pleased to announce its appointment of Dr. Mark A. Turco (Dr. Turco), M.D., F.A.C.C., as President of Genesis MedTech Intervention, North America and CEO of JC Medical, Inc. Dr. Turco will lead the commercial strategy for the Vascular Interventions and Structural Heart Franchises in North America, catalysing Genesis' mission to bring innovative medical technologies to healthcare practitioners and patients.
  • Prior to joining Genesis MedTech, Dr. Turco was the President and CEO of Cardiac Implants LLC, a clinical-stage medical device start-up with a novel treatment for tricuspid valvular heart disease.
  • We look forward to creating a positive impact on our patients and healthcare in North America."
  • Dr. Turco shared similar sentiments, "I am thrilled to join Genesis MedTech Group in its mission to make high-quality healthcare accessible globally.

The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)

Retrieved on: 
Thursday, May 11, 2023

Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.

Key Points: 
  • Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.
  • With the CV-dedicated configuration, Esaote offers best-in-class diagnostic capability and high-level flexibility to cardiologists and mobile service professionals, anytime and anywhere.
  • Leader in the biomedical equipment sector (ultrasound, magnetic resonance imaging, software for managing the diagnostic process).
  • At the end of 2022, the Group had 1,250 employees, with more than half of them in Italy.

The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)

Retrieved on: 
Thursday, May 11, 2023

Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.

Key Points: 
  • Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.
  • With the CV-dedicated configuration, Esaote offers best-in-class diagnostic capability and high-level flexibility to cardiologists and mobile service professionals, anytime and anywhere.
  • Leader in the biomedical equipment sector (ultrasound, magnetic resonance imaging, software for managing the diagnostic process).
  • At the end of 2022, the Group had 1,250 employees, with more than half of them in Italy.

Philips showcases its latest portfolio of cardiology innovations that deliver clinical confidence and efficiency in treating cardiac disease at EuroPCR 2023

Retrieved on: 
Thursday, May 11, 2023

The Philips cardiology portfolio addresses the need for integrating imaging, devices, software, informatics, and services at each point in the cardiac patient journey.

Key Points: 
  • The Philips cardiology portfolio addresses the need for integrating imaging, devices, software, informatics, and services at each point in the cardiac patient journey.
  • Philips’ proven physiology technologies can enable interventionalists to perform ultra-low contrast percutaneous coronary intervention (ULC-PCI) procedures with greater confidence.
  • In line with the company’s commitment to supporting its innovations with clinical evidence, Philips’ clinical partners will present new data during late-breaking sessions at EuroPCR that could help inform treatment for PCI patients.
  • For a full calendar of Philips events, session registration and to learn more about cardiology solutions being showcased in Philips Booth #F20 at EuroPCR 2023, please visit our website .

Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System

Retrieved on: 
Thursday, April 20, 2023

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounce™ Thrombectomy System Retrospective Registry.

Key Points: 
  • Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounce™ Thrombectomy System Retrospective Registry.
  • PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce system for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.
  • The first site to enroll a patient in the registry study was Baton Rouge General Medical Center, Baton Rouge, La.
  • We are confident the PROWL registry will demonstrate these exceptional attributes of the Pounce system in real-world clinical practice.”